USFDA APPROVES DAPAGLIFLOZIN FOR USE IN NON DIABETICS BASED ON DAPA HF

Dear my friends and fellow Colleagues, Here is an update on Dapa HF Trial. Based upon results of DAPA-HF trial, USFDA approves Dapagliflozin for Heart Failure with Reduced Ejection Fraction (HFrEF) in patients with or without Diabetes to reduce the risk of CV death & HHF, Hospitalization for Heart Failure. May, 2020. Regards and thanks, Dr Sepuri Krishna Mohan.

(Edited)

4 Likes

LikeAnswersShare

Yes sir this is latest trial concluded and declared by British heart association It is significant development in treatment of heart failure as well as about dapagliflozin. Yesterday i had discussion on this subject with ADJ of astra zeneca Same conclusion was drawn Thanx for updates

Valuable opinion
0

View 2 other replies

Informative post sir

Thank you doctor
0

Excellent information sir

Valuable opinion
0

Thanks for the update sir

Thank you doctor
0

Diseases Related to Discussion

Cases that would interest you